Ausgewählte Studien

RMD Open. 2023 Dec 19;9(4):e003538. doi: 10.1136/rmdopen-2023-003538. ABSTRACT BACKGROUND: The influence of sex on treatment outcomes during interleukin-12/23 therapy in patients with psoriatic arthritis (PsA) has not been explored. OBJECTIVE: To conduct exploratory post hoc analyses of sex-stratified data from the MUST trial, an investigator-initiated, multicentre, phase 3b study in which patients with active PsA initiating treatment with open-label ustekinumab were randomised to treatment with

Li S, Xia D, Prausnitz MR. Li S, et al. Adv Funct Mater. 2021 Oct 26;31(44):2103359. doi: 10.1002/adfm.202103359. Epub 2021 Jun 21. Adv Funct Mater. …Den ganzen Artikel lesen

Br J Dermatol. 2021 Dec;185(6):e200-e213. doi: 10.1111/bjd.20787. ABSTRACT Linked Article: Maul et al. Br J Dermatol 2021; 185:1160-1168. Psoriasis is a chronic, scaly skin condition affecting about 2·5% of the population. It has a negative impact on people's quality of life, more so in women. It is usually treated with creams but is sometimes severe enough to need strong medicines, which are not always effective. This study examines differences between men and women in their responses to treatm

J Dtsch Dermatol Ges. 2021 Oct;19(10):1463-1475. doi: 10.1111/ddg.14547. Epub 2021 Oct 7. ABSTRACT BACKGROUND AND OBJECTIVES: Documenting patient data in psoriasis clinical practice can improve care, but standardized and transparent documentation is rare. The current project aimed to develop a data set for the documentation of psoriasis in daily practice. MATERIAL AND METHODS: In four online Delphi rounds and one in-person meeting, 27 psoriasis experts allocated variables to a standard, an optim

J Dtsch Dermatol Ges. 2021 Oct;19(10):1463-1477. doi: 10.1111/ddg.14547_g. NO ABSTRACT PMID:34661349 | DOI:10.1111/ddg.14547_g Den ganzen Artikel lesen

Int J Dermatol. 2024 Jan 2. doi: 10.1111/ijd.16915. Online ahead of print. ABSTRACT BACKGROUND: Biological therapy dose modification is a common practice in the long-term treatment of plaque psoriasis. OBJECTIVE: The objective of the study was to determine prevalence, characteristics of patients, effectiveness, treatment survival of secukinumab dose reduction (SEC-DR) strategy and assess its safety and cost implications. METHODS: A retrospective, observational, multicenter cohort study was condu

Harmer B, Lee S, Duong TVH, Saadabadi A. Harmer B, et al. 2024 Feb 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 …Den ganzen Artikel lesen

Jeeyu Choi, Jeeyu Choi School of Dentistry, Pusan National University, Yangsan, Republic of Korea Search for more papers by this author Ikjoon Han, Ikjoon …Den ganzen Artikel lesen

Jeeyu Choi, Jeeyu Choi School of Dentistry, Pusan National University, Yangsan, Republic of Korea Search for more papers by this author Ikjoon Han, Ikjoon …Den ganzen Artikel lesen

Jeeyu Choi, Jeeyu Choi School of Dentistry, Pusan National University, Yangsan, Republic of Korea Search for more papers by this author Ikjoon Han, Ikjoon …Den ganzen Artikel lesen

Dear Editor, Biologic agents selectively targeting interleukin (IL)23 represent a breakthrough in the treatment of patients with moderate–severe …Den ganzen Artikel lesen

Dermatol Ther. 2022 Sep 15:e15831. doi: 10.1111/dth.15831. Online ahead of print. ABSTRACT BACKGROUND: In many countries there are strong incentives for initiation of treatment with biosimilars in biologic-naïve patients and non-medical switch of ongoing treatment with originators, but real-world data regarding the outcome of these treatments are scarce. OBJECTIVES: The objective of this study is to analyze the drug survival of biosimilar adalimumab for treatment of psori

Real-world efficacy of biologics may be insufficiently assessed through common drug survival studies. The objective was thus to examine real-world …Den ganzen Artikel lesen

ORIGINAL ARTICLE Corresponding Author T. Bertelsen Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark DERMBIO, Denmark Trine …Den ganzen Artikel lesen

Am J Clin Dermatol. 2022 Aug 17. doi: 10.1007/s40257-022-00722-y. Online ahead of print. ABSTRACT BACKGROUND: Drug survival, defined as the length of time from initiation to discontinuation of a given therapy, allows comparisons between drugs, helps to predict patient's likelihood of remaining on a specific treatment, and achieving the best decision for each patient in daily clinical practice. OBJECTIVE: The aim of this study was to provide data on drug survival of secukinumab, ixekizumab, broda

ZusammenfassungHintergrundBiologika, die die Interleukine IL-23 and IL-17 hemmen, haben sich in der Behandlung der mittelschweren bis schweren …Den ganzen Artikel lesen

Front Immunol. 2023 Oct 23;14:1283251. doi: 10.3389/fimmu.2023.1283251. eCollection 2023. ABSTRACT Dual targeted therapy (DTT) has emerged as a promising approach in patients with refractory spondyloarthritis (SpA) or psoriatic arthritis (PsA) and extra-musculoskeletal manifestations of both diseases, but its effectiveness/safety ratio still remains unclear. This is a retrospective, real-world multicenter study in refractory SpA and PsA patients with simultaneous use of two biological or synthet

Hautarzt. 2021 Jul;72(7):570-577. doi: 10.1007/s00105-021-04832-2. Epub 2021 Jun 16. ABSTRACT BACKGROUND: The skin is an organ frequently affected by chronic diseases. Inflammatory, immune-mediated dermatoses such as atopic dermatitis and psoriasis show a high prevalence as well as a significant impact on the quality of life of those affected. In a large proportion of cases, atopic dermatitis is associated with a marked change in microbial colonization of both clinically healthy and affected ski

Front Immunol. 2022 Mar 3;13:839945. doi: 10.3389/fimmu.2022.839945. eCollection 2022. ABSTRACT It has been well established that the etiopathogenesis of diverse autoimmune diseases is rooted in the autoreactive immune cells' excessively proliferative state and impaired apoptotic machinery. Survivin is an anti-apoptotic and mitotic factor that has sparked a considerable research interest in this field. Survivin overexpression has been shown to contribute significantly to the development of autoi

SummaryPsoriasis is a common chronic inflammatory skin disease that causes systemic inflammation and severely impacts the patient's quality of life. …Den ganzen Artikel lesen

Wollina U. Wollina U. Dermatol Ther. 2019 Mar;32(2):e12805. doi: 10.1111/dth.12805. Epub 2018 Dec 27. Dermatol Ther. 2019. PMID: 30565362 …Den ganzen Artikel lesen

Full text linksCite Display options Display options Background: Itch is the most bothersome symptom reported by patients with psoriasis. Safe and …Den ganzen Artikel lesen

Dermatol Ther. 2021 Nov 24:e15231. doi: 10.1111/dth.15231. Online ahead of print. ABSTRACT BACKGROUND: Data on the effectiveness and safety of a drug in real-world clinical practice complement the evidence from clinical trials, which are carried out in a different setting. Little has been published on the effectiveness and safety of guselkumab in the treatment of psoriasis in clinical practice. OBJECTIVES: To assess the effectiveness and safety of guselkumab at 24 weeks in patients with moderate

Objective: This study aims to evaluate the effect of functional versus resistance exercise training on the functional capacity and quality of life of …Den ganzen Artikel lesen

RMD Open. 2023 Mar;9(1):e002936. doi: 10.1136/rmdopen-2022-002936. ABSTRACT OBJECTIVE: To investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies. PATIENTS AND METHODS: 1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.3%) with PsA from the COVID-19 registry in patients with rheumatic diseases (COVIDSER) project, were included. Demographics, disease characteristics, Diseas